- Eiger to Present at Jefferies 2019 London Healthcare Conference
- Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
- Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
- Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
- Eiger to Present at Cantor 2019 Global Healthcare Conference
As of last trade
Eiger BioPharmaceuticals Inc (72C1:STU) traded at 11.60, -12.90% below its 52-week high of 13.32, set on Apr 09, 2019.
7.74Dec 27 201813.32Apr 09 2019
Markit short selling activity
|Market cap||312.92m USD|
|EPS (TTM)||-3.33 |
Data delayed at least 15 minutes, as of Dec 11 2019.